Table 1. Baseline characteristics by aldosterone quartile.
Serum aldosterone, ng/dLP trend
Quartile 1 (<7.11)Quartile 2 (7.11–9.26)Quartile 3 (9.26–12.77)Quartile 4 (>12.77)
n269268268268
Mean age, years (SD)63 (11.7)62 (10.6)63 (11.9)65 (11.7)0.005
Female94 (34.9)85 (31.7)75 (28.0)88 (32.8)0.428
Index diagnosis
    ST-elevation MI145 (53.9)167 (62.3)164 (61.2)152 (56.7)0.584
    Prior MI59 (21.9)48 (17.9)64 (23.9)50 (18.7)0.726
Coronary risk factors
    Hypertension175 (65.1)166 (61.9)183 (68.3)183 (68.3)0.216
    Hyperlipidemia164 (61.0)153 (57.1)131 (48.9)137 (51.1)0.0055
    Current smoker99 (36.8)99 (36.9)89 (33.2)63 (23.5)0.0007
    Diabetes53 (19.7)58 (21.6)54 (20.2)54 (20.2)0.99
Body mass index ≥ 30 kg/m272 (27.1)60 (23.0)72 (27.4)77 (29.5)0.343
Estimated glomerular filtration rate <60 mL · min−1 · (1.73 m2)−140 (14.9)38 (14.2)49 (18.3)71 (26.5)0.0002
Prior ACE/ARB70 (26.0)80 (29.9)74 (27.6)92 (34.3)0.068
Mean LVEF (SD)b52 (8.1)53 (8.3)53 (7.8)53 (8.0)0.314
Neurohormonal biomarkers, geometric mean (SD)
    Plasma renin activity, ng/mL per h1.02 (4.80)1.28 (5.23)1.35 (4.85)1.78 (5.56)<0.001
    NT-proBNP, ng/L961.92 (2.56)843.92 (2.34)908.99 (2.60)873.09 (2.64)0.305
  • a Data are n (%) unless noted otherwise. Quartiles exclude extreme values for change of aldosterone from baseline to week 8 (>1000 pmol/L). To convert aldosterone concentrations in ng/dL to pmol/L, multiply by 27.74.

  • b n = 909.